| 生物活性 |
Isolinderalactone is a sesquiterpene with anticancer, anti-inflammatory, and neuroprotective effects that inhibits VEGF expression and VEGFR2 tyrosine phosphorylation, reduces viability and induces apoptosis (apoptosis) in U-87 glioblastoma (GBM) cells and colorectal cancer (CRC) cells, induces G2/M cell cycle arrest, reactive oxygen species (ROS) generation, and pJNK/p38 MAPK activation in colorectal cancer (CRC) cells, blocks LPS (MS-X54539)-induced NF-κB activation while activating the Nrf2-HMOX1 signaling pathway in RAW264.7 macrophages, ameliorates cognitive impairment in APP/PS1 mice, and can be used for research on glioblastoma (GBM), colorectal cancer, Alzheimer's disease, and acute lung injury. |
体外研究 (In Vitro) |
Isolinderalactone (0.5-2.5 μg/mL, 24-72 h) 抑制 U-87 胶质母细胞瘤细胞生长。
Isolinderalactone (0.5-2.5 μg/mL, 48 h) 通过降低 BCL-2、survivin 和 XIAP 表达,增加 cleaved caspase-3,并诱导 DNA 断裂,激活 U-87 GBM 细胞的凋亡途径,从而促进细胞凋亡。
Isolinderalactone (0.5-2 μg/mL, 48 h) 抑制 U-87 GBM 细胞中 VEGF 表达,并抑制人脑微血管内皮细胞 (HBMECs) 的 VEGF 诱导血管生成。
Isolinderalactone (2 μg/mL, 8 days) 在三维微流控芯片中抑制血管生成萌发。
Isolinderalactone (2.5-5 μg/mL, 48 h) 降低 U-87 细胞中 HIF 表达和活性以及 HBMECs 中 VEGFR2 激活。
Isolinderalactone (0-9 μM, 24-48 h) 抑制结直肠癌细胞 (HCT116, HCT116-OxR, HT29, HT29-OxR) 的增殖和集落形成。
Isolinderalactone (0-9 μM, 48 h) 在结直肠癌细胞中诱导凋亡、G2/M 期细胞周期停滞、活性氧 (ROS) 生成和内质网应激。
Isolinderalactone (0-9 μM, 48 h) 在结直肠癌细胞中诱导凋亡,通过线粒体和 caspase 依赖途径,可能通过调节 JNK/p38 MAPK 激活,其中 ROS 发挥关键作用。
Isolinderalactone (10 μM, 2-27 h) 减轻 Aβ1-42 诱导的细胞损伤并降低 PC12 细胞中的神经毒性。
Isolinderalactone (10 μM, 27 h) 通过抑制 JNK 减少 PC12 细胞中的神经元细胞损伤。
Isolinderalactone (0.5-10 μM, 19 h) 在 RAW264.7 细胞、MH-S 细胞和骨髓源性巨噬细胞 (BMDMs) 中抑制 LPS 或 TNF-α 诱导的炎症反应。
Isolinderalactone (1-10 μM, 13 h) 在 LPS 刺激的 RAW264.7 巨噬细胞中抑制促炎酶和细胞因子的 mRNA 表达。
Isolinderalactone (1-10 μM, 2-9 h) 在 RAW264.7 巨噬细胞中阻断 LPS 诱导的 NF-κB 活化,同时激活 Nrf2-HMOX1 通路。
Cell Viability Assay
| Cell Line: |
U-87 GBM cells and HBMECs |
| Concentration: |
0.5, 1, 2, 2.5 μg/mL |
| Incubation Time: |
24, 48, 72 h |
| Result: |
Inhibited cell viability in a dose-dependent manner.
Decreased VEGF-induced HBMEC proliferation in a dose-dependent manner.
|
Western Blot Analysis
| Cell Line: |
U-87 GBM cells and HBMECs |
| Concentration: |
0.5, 1, 2.5,5 μg/mL |
| Incubation Time: |
48 h |
| Result: |
Decreased BCL-2, survivin, and XIAP expression.
Increased the level of cleaved caspase-3 and cleaved PARP.
Decreased the expression of the potent angiogenic factor, VEGF.
Decreased HIF expression and activity in U-87 cells.
Reduced phosphorylation of VEGFR2 in HBMECs.
|
Immunofluorescence
| Cell Line: |
U-87 GBM cells |
| Concentration: |
2.5 μg/mL |
| Incubation Time: |
48 h |
| Result: |
Showed predominantly bright γ-H2AX nuclear staining.
|
Cell Viability Assay
| Cell Line: |
HCT116, HCT116-OxR, HT29, and HT29-OxR cells |
| Concentration: |
3, 6, 9 μM |
| Incubation Time: |
24, 48 h |
| Result: |
Suppressed colorectal cancer cells proliferation with IC50 values of 8.05 μM (HCT116), 5.13 μM (HCT116-OxR), 10.38 μM (HT29) and 9.46 μM (HT29-OxR).
|
Cell Cycle Analysis
| Cell Line: |
HCT116, HCT116-OxR, HT29, and HT29-OxR cells |
| Concentration: |
3, 6, 9 μM |
| Incubation Time: |
48 h |
| Result: |
Contributed to G2/M phase cell cycle arrest.
|
Western Blot Analysis
| Cell Line: |
HCT116, HCT116-OxR, HT29, and HT29-OxR cells |
| Concentration: |
3, 6, 9 μM |
| Incubation Time: |
48 h |
| Result: |
Increased the expression levels of ER stress related proteins (GRP78, CHOP, DR4, and DR5).
Activated JNK/p38 MAPK.
Increased the levels of pro-apoptotic proteins (Bim and Bax), apaf-1, and cleaved (c)-PARP.
Decreased expression levels of anti-apoptotic proteins (Mcl-1, Bid, Bcl-xL and Bcl-2), mitochondrial cyto c and caspase 3 in a dose-dependent manner.
|
Western Blot Analysis
| Cell Line: |
Aβ1-42-induced PC12 cells |
| Concentration: |
10 μM |
| Incubation Time: |
27 h |
| Result: |
Decreased Bax expression and intracellular levels of caspase-3 activation and increased Bcl2 levels.
Decreased the level of p-JNK, but had no significant effect on ERK and P38MAPK.
|
Real Time qPCR
| Cell Line: |
LPS-exposed RAW264.7 macrophages |
| Concentration: |
1, 10 μM |
| Incubation Time: |
13 h |
| Result: |
Decreased the mRNA levels of iNOS, COX2, IL-1β, IL-6, and TNF-α.
|
Western Blot Analysis
| Cell Line: |
LPS-exposed RAW264.7 macrophages |
| Concentration: |
1, 5, 10 μM |
| Incubation Time: |
2, 9 h |
| Result: |
Down-regulated LPS-induced phosphorylation of IKKα/β and the level of NF-κB p65.
Increased the protein level of Nrf2 protein in the cytoplasmic fraction and nuclear fraction.
|
|
体内研究 (In Vivo) |
Isolinderalactone (1-5 mg/kg,腹腔注射,每隔一天一次,共 12 天) 抑制人 GBM 异种移植小鼠模型中的肿瘤生长。
Isolinderalactone (2.5-5 mg/kg,腹腔注射,每隔一天一次,共 16 天) 减少人 GBM 异种移植模型中的肿瘤生长和血管生成。
Isolinderalactone (5 mg/kg,腹腔注射,每天一次,共 6 天) 在小鼠体内 Matrigel 实验中抑制 VEGF 介导的血管生成。
Isolinderalactone (1-10 mg/kg,腹腔注射,每天一次,共 30 天) 改善 APP/PS1 小鼠的学习和记忆缺陷。
Isolinderalactone (2.5-10 mg/kg,腹腔注射,每日一次,持续 5 天) 可减轻 LPS 诱导的小鼠肺部炎症损伤。
| Animal Model: |
U-87 GBM cells (3 × 106 cells/100 μL of serum-free DMEM) were subcutaneously implanted into the right flank of the BALB/C nude mice
|
| Dosage: |
1, 2.5, 5 mg/kg |
| Administration: |
i.p., every other day for 12 days |
| Result: |
Reduced tumor volume and weight
Showed no differences on body weight.
Increased cleaved caspase-3 fluorescence.
Showed a significantly higher number of TUNEL-positive cells.
|
| Animal Model: |
U-87 GBM cells (3 × 106 cells/100 μL of serum-free DMEM) were subcutaneously implanted into the right flank of the BALB/C nude mice
|
| Dosage: |
2.5, 5 mg/kg |
| Administration: |
i.p., every other day for 16 days |
| Result: |
Decreased tumor volume and suppressed tumor progression.
Inhibited tumor angiogenesis.
Reduced VEGF immunoreactivity.
|
| Animal Model: |
C57BL/6 mice (6-week-old, male)
|
| Dosage: |
5 mg/kg |
| Administration: |
i.p. daily for 6 days |
| Result: |
Decreased hemoglobin concentration and CD31 staining.
Inhibited VEGF-induced new vessel formation in vivo.
|
| Animal Model: |
10-month-old APP/PS1 transgenic mice
|
| Dosage: |
1, 10 mg/kg |
| Administration: |
i.p. daily for 30 days |
| Result: |
Enhanced the exploration of the novel object by the mice.
Ameliorated learning and memory deficits in APP/PS1mice.
Reduced the level of APP/β-amyloid.
Increased the levels of synapse-associated proteins, including PSD95 and Map2.
Reduced neuronal apoptosis in the cortex and hippocampus.
Increased the SOD content and decreased MDA levels in the hippocampus.
Increased Bcl2 levels, decreased Bax, p-JNK expression, and decreased caspase-3 activation.
|
| Animal Model: |
Male Institute of Cancer Research (ICR) mice (SPF grade, 20-22 g, 6 weeks old) injected with LPS (15 mg/kg)
|
| Dosage: |
2.5-10 mg/kg |
| Administration: |
i.p., daily for 5 days |
| Result: |
Improved the lung injury scores.
Reduced the MPO activity in LPS-exposed lung tissue.
Reduced the levels of PGE2, IL-1β, IL-6, and TNF-α.
|
|